Abstract
Clinical trials with cytokine inhibitors have failed to show efficacy and confirm preclinical findings in sepsis and systemic inflammatory response syndromes. However, a better understanding of the pathogenesis of sepsis syndrome, and of proinflammatory cytokine signal transduction pathways, including the role of nuclear factor kappa B and inflammation-induced apoptosis, have provided new therapeutic opportunities for cytokine and anticytokine therapies.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: Current opinion in clinical nutrition and metabolic care
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
